Edition:
United States

Voyager Therapeutics Inc (VYGR.OQ)

VYGR.OQ on NASDAQ Stock Exchange Global Select Market

13.60USD
3:59pm EST
Change (% chg)

$-0.17 (-1.23%)
Prev Close
$13.77
Open
$13.79
Day's High
$14.11
Day's Low
$13.30
Volume
122,010
Avg. Vol
144,387
52-wk High
$25.93
52-wk Low
$8.10

Latest Key Developments (Source: Significant Developments)

Voyager Therapeutics prices public offering of 4.50 mln common shares at $12/shr
Tuesday, 7 Nov 2017 10:54pm EST 

Nov 7 (Reuters) - Voyager Therapeutics Inc :Voyager Therapeutics announces pricing of public offering of common stock.Says public offering of 4.50 million common shares priced at $12.00per share.  Full Article

Voyager Therapeutics announces proposed offering of common stock
Monday, 6 Nov 2017 04:14pm EST 

Nov 6 (Reuters) - Voyager Therapeutics Inc :Voyager Therapeutics announces proposed offering of common stock.Voyager Therapeutics Inc - ‍commencing an underwritten public offering of $75 million of shares of its common stock​.  Full Article

Voyager Therapeutics reports Q3 GAAP loss per share $0.89
Thursday, 2 Nov 2017 04:01pm EDT 

Nov 2 (Reuters) - Voyager Therapeutics Inc :Voyager Therapeutics Inc reports third quarter 2017 financial results and corporate highlights.Q3 GAAP loss per share $0.89.Q3 earnings per share view $-0.72 -- Thomson Reuters I/B/E/S.Voyager Therapeutics Inc - ‍total cash, cash equivalents, and marketable debt securities as of september 30, 2017 were $125.6 million​.Voyager Therapeutics Inc - ‍continues to expect to end 2017 with total cash, cash equivalents, and marketable debt securities of about $90 million to $100 million​.Voyager Therapeutics Inc - ‍existing cash, cash equivalents, marketable debt securities will be sufficient to fund operating expenses and capex requirements into 2019​.  Full Article

Voyager Therapeutics reports positive results from ongoing trial for advanced parkinson’s disease
Wednesday, 6 Sep 2017 07:00am EDT 

Sept 6 (Reuters) - Voyager Therapeutics Inc :Voyager Therapeutics announces positive results from ongoing Phase 1b trial of VY-AADC01 for advanced parkinson’s disease.Pivotal phase 2-3 program on track to begin during late 2017 and to dose first patient during first half of 2018.Robust and durable clinical effects achieved with substantial reductions in daily oral levodopa use and other parkinson's medications.Voyager Therapeutics Inc - one-time administrations of VY-AADC01 well-tolerated out to 24 months.Voyager Therapeutics Inc - VY-AADC01 improved multiple measures of patients' motor function and activities of daily living in cohorts 2 and 3.  Full Article

Voyager Therapeutics announces clinical trial update with VY-AADC01 for advanced Parkinson's disease
Monday, 26 Jun 2017 07:05am EDT 

June 26 (Reuters) - Voyager Therapeutics Inc :Voyager Therapeutics announces clinical trial update with VY-AADC01 for advanced Parkinson's disease.Voyager Therapeutics Inc - Administration of VY-AADC01 with this posterior approach was well-tolerated by patient.Voyager Therapeutics Inc - No serious adverse events were reported and patient was discharged from hospital day after surgery.  Full Article

Voyager Therapeutics reports Q1 GAAP loss per share $0.65
Tuesday, 9 May 2017 04:10pm EDT 

May 9 (Reuters) - Voyager Therapeutics Inc :Voyager Therapeutics reports first quarter 2017 financial results and corporate highlights.Q1 GAAP loss per share $0.65.Q1 earnings per share view $-0.53 -- Thomson Reuters I/B/E/S.Voyager Therapeutics Inc - Collaboration revenues of $1.5 million for Q1 of 2017 compared to collaboration revenues of $4.8 million for Q1 of 2016..  Full Article

Voyager Therapeutics Q4 gaap loss per share $0.57
Wednesday, 15 Mar 2017 07:05am EDT 

Voyager Therapeutics Inc : Voyager therapeutics reports fourth quarter and full year 2016 financial results and corporate highlights . Q4 gaap loss per share $0.57 . Q4 earnings per share view $-0.46 -- Thomson Reuters I/B/E/S .Voyager therapeutics inc - collaboration revenues of $2.4 million for q4 of 2016 compared to collaboration revenues of $4.9 million for q4 of 2015.  Full Article

Voyager Therapeutics announces positive interim results from phase 1B trial of VY-AADC01
Wednesday, 7 Dec 2016 04:05pm EST 

Voyager Therapeutics Inc : Says VY-AADC01 dose-dependently improved measures of motor function and enhanced response to levodopa at 6 and 12 months . Says administration of VY-AADC01 was well-tolerated . Says program on track to report cohort 3 data mid-2017 and to begin placebo-controlled trial Q4, 2017 .Voyager therapeutics announces positive interim results from phase 1B trial of VY-AADC01 for advanced parkinson’s disease.  Full Article

Voyager Therapeutics Q2 gaap loss per share $0.37
Thursday, 11 Aug 2016 07:05am EDT 

Voyager Therapeutics Inc : Q2 gaap loss per share $0.37 . Voyager therapeutics provides second quarter 2016 investor update . Q2 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S .Voyager continues to expect to end 2016 with cash, cash equivalents and marketable securities of $160.0 million.  Full Article

Voyager Therapeutics reports Q1 loss per share of $0.29
Thursday, 12 May 2016 07:00am EDT 

Voyager Therapeutics Inc - : Voyager Therapeutics Inc says remain on track to deliver top-line, proof-of-concept clinical results for VY-AADC01 in Q4 . Remains on track to file an investigational new drug application in late 2017 for its pipeline program, VY-SOD101 for monogenic form of ALS . Voyager therapeutics provides first quarter 2016 investor update . Q1 loss per share $0.29 .Q1 earnings per share view $-0.38 -- Thomson Reuters I/B/E/S.  Full Article